Biocon Share Price

RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low

Have to keep R&D spends at 12% of revenue: Biocon's Kiran Mazumdar-Shaw

Viatris deal-related expenses drag Biocon's Q3 net into Rs 42 cr loss

MSCI revision: CG Power, Bank Baroda look bullish on charts; avoid Biocon

Please find enclosed the press release titled Biocon Foundation Wins the Prestigious IHW Gold Award for Diseases Screening Initiative of the Year for 2022.The above information will also be available on the website of the Company at www.biocon.com.

In Continuation to our letter dated December 20 2022 seeking approval of the members by way of Postal Ballot through the remote e-voting process on the resolutions as set out in the Postal Ballot Notice dated December 19 2022 please find enclosed:1. Voting results pursuant to Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulation) enclosed and marked as Annexure-1;2. Scrutinizers Report dated January 23 2023 pursuant to Section 110 of the Companies Act 2013 read with Rule 22 of the Companies (Management and Administration) Rules 2014 enclosed and marked as Annexure-2.

This is to certify that the details of securities dematerialized and rematerialized during the quarter ended December 31 2022 as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 have been furnished to all the Stock Exchanges where the shares of Biocon Limited are listed.The certificate from our RTA i.e. M/s. KFin Technologies Limited (Formerly known as KFin Technologies Private Limited) dated January 4 2023 confirming the above is enclosed for your reference.

This is to certify that the details of securities dematerialized and rematerialized during the quarter ended December 31 2022 as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 have been furnished to all the Stock Exchanges where the shares of Biocon Limited are listed.The certificate from our RTA i.e. M/s. KFin Technologies Limited (Formerly known as KFin Technologies Private Limited) dated January 4 2023 confirming the above is enclosed for your reference.

Please find below a Company Statement.The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for the Insulin-R product filed by Biocon Biologics. The CRL cites additional data required in the BLA submission and an expectation of a satisfactory implementation of a CAPA plan pertaining to the Pre-Approval Inspection of our Bangalore facilities in Aug22. We are in the process of comprehensively addressing the CRL. - Company Spokesperson Biocon Biologics.The above information will also be available on the website of the Company at www.biocon.com.